To The Moon

$Tempus AI(TEM)$ Where Data-Rich Precision Medicine Meets Scalable AI Source: Tempus AI Q1 Investor Presentation: Summary Tempus AI is a Chicago-based health-tech company on a mission to make every cancer diagnosis—and eventually every serious disease—an algorithmically informed decision. The firm combines high-throughput genomic testing with one of the world’s largest, fully-consented clinical-outcomes databases. By structuring 40-plus million patient records into a searchable, machine-learning platform, Tempus gives oncologists and drug developers real-time insight into which therapies work, why they work, and for whom. Dual-engine model – Tempus runs CLIA-certified labs that process hundreds of thousands of DNA/RNA samples a year, generating ste

$Tempus AI(TEM)$  $$$

$Tempus AI(TEM)$    

$Tempus AI(TEM)$  Tempus AI’s recent 8% intraday rally following the launch of their new Xm test shows that investors are optimistic about the potential of this tool to monitor immunotherapy responses in advanced cancer patients. This kind of innovation could drive significant growth if the test proves effective and gains adoption, which explains the positive market reaction despite recent challenges. However, the short report from Spruce Point last week, which led to a 20% drop in TEM’s stock, raises serious concerns about the company’s product integrity, management credibility, and financial transparency. These issues can’t be ignored, as they pose real risks to the company’s long-term prospects. The rally could be a short-term rebound fuele

$Tempus AI(TEM)$ is up 15% after launching AI agents directly into Electronic Healthcare Records (EHRs).Why did the $Tempus AI(TEM)$ price go up?The new test is a game-changer: Tempus came out with this cool new test called xM. It’s like a super-smart way to monitor how cancer patients are responding to immunotherapy. Instead of waiting for symptoms to show up, doctors can get early insights into what’s happening with the cancer cells just by analyzing a blood sample. This helps them tweak treatments way ahead of time. The market loves this kind of innovation, so investors got excited and the stock price jumped.AI is now in hospitals: Tempus embedded over 1,000 AI helpers directly into hospital electronic heal

$Tempus AI(TEM)$  not sure what TEM is, what's your opinion on this stock? Come comment for coins @mary__  @LULU ROCKET  @JiaDeName  @Mr_Hotpot  @Billion  

$TEM 20260116 40.0 PUT$  

$TEM VERTICAL 250620 PUT 50.0/PUT 45.0$ Sharing my Tempus AI bullish credit put spread.  Also buying $TEM VERTICAL 250718 CALL 60.0/CALL 65.0$ with the credit. Betting on a bullish rebound after 20% plunge from short seller report. 

Shares of Tempus AI (NASDAQ: TEM) plummeted nearly 20% after a scathing short report from Spruce Point raised alarm bells about the company’s fundamentals. Spruce Point's report questioned the credibility of Tempus AI’s management, the integrity of its AI-related products, and its financial reporting. Tempus AI (TEM) At the heart of the report is a bold accusation: Tempus AI’s branding is disconnected from its actual financial performance. In 2024, AI-related revenue was reported at just $12.4 million—less than 2% of the company’s total revenue of $693.4 million. The previous year, AI revenue was only $5.5 million. I’m skeptical—regardless of the short report. There are several red flags that make TEM stock unattractive to me at current levels: Lack of profitability: Tempus AI’s net income

Wow wow wow wow wow wow wow

Tempus AI ( $Tempus AI(TEM)$ ) stock took a brutal 20% hit, sliding to $55 after a scathing short report from Spruce Point sent shockwaves through the market. The report throws shade on the precision medicine company’s product integrity, management credibility, and financial reporting practices, alleging a gaping chasm between its flashy AI branding and the reality of its books. With AI revenue a measly $12.4 million in 2024—less than 2% of its $693.4 million total, down from $5.5 million the prior year—investors are left reeling. Is this a red flag signaling a deeper collapse, or a golden buying opportunity for savvy traders? Let’s dig into the chaos and find the signal. The Short Report’s Bombshell Claims Spruce Point’s forensic dive paints a gri

I wouldn't get my foot into this for now, given that there are red flag.

$Tempus AI(TEM)$  give it a try , once risk management is taken care of.

AppLovin jumped 11.9% after the digital advertising company posted first-quarter earnings of $1.67 a share, beating Wall Street estimates of $1.44, as revenue rose 40% from a year earlier to $1.48 billion. That also exceeded expectations. The company also said it reached an agreement to sell its mobile ga

hmmm 🤔 Current chart 📉 is Super Bearish with the markets reacted to the Short Report. I won't be looking to scoop 🪏 this... it's More prudent to wait & see 🙈.

This Year, Short Sellers Are Targeting These Soaring Stocks.The last time this kind of short-selling activity occurred was with $AppLovin Corporation(APP)$ , but AppLovin managed to withstand multiple short reports and delivered an impressive earnings report this season.The short report raises concerns about $Tempus AI(TEM)$ AI’s leadership, pointing out that CEO Eric Lefkofsky has been linked to companies that experienced financial scandals, including bankruptcies and restatements. The report also questions the company’s partnerships and joint ventures, suggesting potential round-tripping and related-party transactions.The report further scrutinizes Tempus AI’s billing practices, highlighting the company’s

$Tempus AI(TEM)$  

$Tempus AI(TEM)$ Where Data-Rich Precision Medicine Meets Scalable AI Source: Tempus AI Q1 Investor Presentation: Summary Tempus AI is a Chicago-based health-tech company on a mission to make every cancer diagnosis—and eventually every serious disease—an algorithmically informed decision. The firm combines high-throughput genomic testing with one of the world’s largest, fully-consented clinical-outcomes databases. By structuring 40-plus million patient records into a searchable, machine-learning platform, Tempus gives oncologists and drug developers real-time insight into which therapies work, why they work, and for whom. Dual-engine model – Tempus runs CLIA-certified labs that process hundreds of thousands of DNA/RNA samples a year, generating ste

$Tempus AI(TEM)$ is up 15% after launching AI agents directly into Electronic Healthcare Records (EHRs).Why did the $Tempus AI(TEM)$ price go up?The new test is a game-changer: Tempus came out with this cool new test called xM. It’s like a super-smart way to monitor how cancer patients are responding to immunotherapy. Instead of waiting for symptoms to show up, doctors can get early insights into what’s happening with the cancer cells just by analyzing a blood sample. This helps them tweak treatments way ahead of time. The market loves this kind of innovation, so investors got excited and the stock price jumped.AI is now in hospitals: Tempus embedded over 1,000 AI helpers directly into hospital electronic heal

Tempus AI ( $Tempus AI(TEM)$ ) stock took a brutal 20% hit, sliding to $55 after a scathing short report from Spruce Point sent shockwaves through the market. The report throws shade on the precision medicine company’s product integrity, management credibility, and financial reporting practices, alleging a gaping chasm between its flashy AI branding and the reality of its books. With AI revenue a measly $12.4 million in 2024—less than 2% of its $693.4 million total, down from $5.5 million the prior year—investors are left reeling. Is this a red flag signaling a deeper collapse, or a golden buying opportunity for savvy traders? Let’s dig into the chaos and find the signal. The Short Report’s Bombshell Claims Spruce Point’s forensic dive paints a gri

Shares of Tempus AI (NASDAQ: TEM) plummeted nearly 20% after a scathing short report from Spruce Point raised alarm bells about the company’s fundamentals. Spruce Point's report questioned the credibility of Tempus AI’s management, the integrity of its AI-related products, and its financial reporting. Tempus AI (TEM) At the heart of the report is a bold accusation: Tempus AI’s branding is disconnected from its actual financial performance. In 2024, AI-related revenue was reported at just $12.4 million—less than 2% of the company’s total revenue of $693.4 million. The previous year, AI revenue was only $5.5 million. I’m skeptical—regardless of the short report. There are several red flags that make TEM stock unattractive to me at current levels: Lack of profitability: Tempus AI’s net income

$Tempus AI(TEM)$  Tempus AI’s recent 8% intraday rally following the launch of their new Xm test shows that investors are optimistic about the potential of this tool to monitor immunotherapy responses in advanced cancer patients. This kind of innovation could drive significant growth if the test proves effective and gains adoption, which explains the positive market reaction despite recent challenges. However, the short report from Spruce Point last week, which led to a 20% drop in TEM’s stock, raises serious concerns about the company’s product integrity, management credibility, and financial transparency. These issues can’t be ignored, as they pose real risks to the company’s long-term prospects. The rally could be a short-term rebound fuele

This Year, Short Sellers Are Targeting These Soaring Stocks.The last time this kind of short-selling activity occurred was with $AppLovin Corporation(APP)$ , but AppLovin managed to withstand multiple short reports and delivered an impressive earnings report this season.The short report raises concerns about $Tempus AI(TEM)$ AI’s leadership, pointing out that CEO Eric Lefkofsky has been linked to companies that experienced financial scandals, including bankruptcies and restatements. The report also questions the company’s partnerships and joint ventures, suggesting potential round-tripping and related-party transactions.The report further scrutinizes Tempus AI’s billing practices, highlighting the company’s

$Tempus AI(TEM)$  $$$

$Tempus AI(TEM)$    

$Tempus AI(TEM)$  not sure what TEM is, what's your opinion on this stock? Come comment for coins @mary__  @LULU ROCKET  @JiaDeName  @Mr_Hotpot  @Billion  

$TEM VERTICAL 250620 PUT 50.0/PUT 45.0$ Sharing my Tempus AI bullish credit put spread.  Also buying $TEM VERTICAL 250718 CALL 60.0/CALL 65.0$ with the credit. Betting on a bullish rebound after 20% plunge from short seller report. 

$TEM 20260116 40.0 PUT$  

AppLovin jumped 11.9% after the digital advertising company posted first-quarter earnings of $1.67 a share, beating Wall Street estimates of $1.44, as revenue rose 40% from a year earlier to $1.48 billion. That also exceeded expectations. The company also said it reached an agreement to sell its mobile ga

hmmm 🤔 Current chart 📉 is Super Bearish with the markets reacted to the Short Report. I won't be looking to scoop 🪏 this... it's More prudent to wait & see 🙈.

Wow wow wow wow wow wow wow

I wouldn't get my foot into this for now, given that there are red flag.

$Tempus AI(TEM)$  give it a try , once risk management is taken care of.

$Tempus AI(TEM)$